GlassScriptPhysician profile
Olivia Jane Dizon
NPI 1346096575
$1,030.65
in general payments reported to CMS, 2019-2025
17 companies · $818 in 2025
The $818 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $213 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $208.32 | 2024-2025 | |
| Novo Nordisk INC | $168.12 | 2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $130.31 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $120.67 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $68.36 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $46.88 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.47 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $43.43 | 2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $42.01 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $22.92 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $22.82 | 2025 | Omnipod |
| Tactile Systems Technology INC | $20.90 | 2025 | Nimbl, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $19.65 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $17.60 | 2025 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.37 | 2025 | Arexvy, Shingrix |
| Amgen INC. | $15.25 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Dizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.